All right. Thank you.
Around cost-effectiveness, and again, it's probably a debate for another day, but was there debate at the table you had in Montreal around...? I understand doing cost-effectiveness for a variety of reasons in a variety of ways. It seems to me somewhat more difficult to do cost-effectiveness either around rare disorders or around oncology drugs, because no matter what, it's going to be expensive. So it's not going to be cost-effective from a money perspective.
I don't know if at the tables you sit at cost-effectiveness has been explored in a broader way, in a more socialistic, cultural, dynamic way, as well as just the money part. Has anybody been part of that kind of discussion?